Thermo Fisher Scientific Human CDCA8 Synthetic Peptide

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

-

Blocking Assay (BLOCK)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

purified

Storage buffer

PBS, pH 7.2, with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C

Product Specific Information

This peptide corresponds to 19 amino acids near the amino terminus of human CDCA8

PEP-0696 can be used as a blocking peptide with polyclonal antibody PA5-20576.

Target Information

CDCA8 is a component of a chromosomal passenger complex (CPC) required for stability of the bipolar mitotic spindle. The chromosomal passenger complex, which includes Survivin, CDCA8, INCENP and Aurora-B, is known to play crucial roles during mitosis and cell division. It was found that CDCA8 interacting with Aurora-B, INCENP and Survivin, increases during G2/M phase and then reduces after exit from M phase. CDCA8 is cell cycle regulated, down-regulated in response to p53/Rb-signaling, and up-regulated in many types of cancerous tissues. In Drosophila cells, inactivation of CDCA8 results in polyploidy, delayed mitosis and abnormal tissue development, indicating its critical role for cell proliferation. Recent studies show that CDCA8 is essential for cell proliferation during early embryonic development, and its early embryonic lethality cannot be rescued by the loss of p53. Its aberrant expression is linked to a poor prognosis for gastric cancer.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.